Navigation Links
Transposagen Receives Over $4.3M in Grants and Investment
Date:6/21/2013

LEXINGTON, Ky., June 21, 2013 /PRNewswire-iReach/ -- Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced today that it is the recipient of over $2,975,426 in additional Small Business Innovation Research (SBIR) funding; $1,975,426 from the National Institutes of Health (NIH) and $1,000,000 from the KY Cabinet for Economic Development (CED). Transposagen's project titled: Creation of Hyperactive Transposons for Mutagenesis in Rodents will further develop Transposagen's piggyback(TM) DNA Modification System. The piggyBac(TM) technology and other Transposagen technologies, such as site-specific nucleases called XTN(TM) TALENs, are genome modification tools used for the creation of custom cell lines and rat and mouse models.

(Photo: http://photos.prnewswire.com/prnh/20130621/CG36249)

The NIH performs comprehensive external peer review using experts from academia and industry to assess the scientific merit, technical merit, and commercial application of the proposed technology. The following was stated in the NIH's Project Summary Statement, "Transposon mediated mutagenesis has the potential to generate knockout embryonic stem cells and rats for a large number of genes. These are likely to become powerful tools in the researchers' toolkit. Impact on a broad spectrum of research areas is likely to be huge and sustained."

"This most recent award from the NIH and the CED further validates the importance of Transposagen's core technologies," said Dr. Eric Ostertag, CEO of Transposagen Biopharmaceuticals, Inc. "The focus of this grant is the creation of genetically modified rat models for studying human disease. However, Transposagen also provides these technologies to researchers for the creation of nearly any type of genetic modification in any model organism or cell line."

As part of the conditions of the award from the CED, Transposagen was required to match the $1,000,000 grant with at least $1,000,000 in investment money. Transposagen raised over $1.3 million in its Series A investment round, mostly from local angel investors. Transposagen has received grant funding and investments of over $8.0 million since 2005.

About Transposagen Biopharmaceuticals:

Transposagen Biopharmaceuticals, Inc. is a worldwide leader in technologies and services for genetic modification. Transposagen is dedicated to providing better disease models through genetic modification. Transposagen specializes in custom and off-the-shelf XTN(TM) site-specific nucleases, animal models, cell lines, stem cells and cutting-edge research tools and technologies to improve drug discovery and development research.

Contact:
Jack Crawford
535 W. Second Street
Lexington, KY 40508
(315) 351-9115

Media Contact: Jack Crawford, Transposagen Biopharmaceuticals, (315) 351-9115, jcrawford@transposagenbio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Transposagen Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. GenoSpace Founder and CEO Receives "Champions of Change" Award from White House
2. Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval
3. AMRI Burlington Receives DEA Approval to Handle Controlled Substances
4. zuChem Receives Two Polyol Patents
5. Case Western Reserve University, in Collaboration with NDI Medical, SPR Therapeutics and Valtronic Technologies, Receives $3 Million from Ohio Third Frontier Commission
6. IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology
7. Nanoelectronics Center at UT Austin receives $7.8 million grant
8. Vermillions OVA1 Receives New Statement by Society of Gynecologic Oncology
9. The Renewable Corporation (RNWB) through its wholly owned subsidiary EcoSmart Surface & Coating Technologies receives results from Product Test Service.
10. New York Blood Centers Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development
11. CardioDx Receives College of American Pathologists (CAP) Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  Driven by ... biotechnology are now the fastest growing categories, finds ... Specialty Actives in Personal Care: Multi-regional Market Analysis ... and management consulting firm Kline. "Biotechnology ... that make them more effective for skin and ...
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017  MIODx ... license for two key immunotherapy technologies from the ... technology provides a method to monitor a patient ... as PD-L1 and CTLA-4.  The second license extends ... a patient is likely to have an immune-related ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... in a published evaluation of multiple immunoassay-based threat detection technologies by researchers ... Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to have the ...
Breaking Biology Technology:
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist Medical ... its new chief executive officer (CEO). Freischlag joins the ... John D. McConnell , M.D., who last year announced ... the Medical Center, after leading it since 2008.   ... scope of Wake Forest Baptist,s academic health system, which ...
(Date:2/8/2017)... About Voice Recognition Biometrics Voice recognition biometrics ... a stored voiceprint template. Acoustic features of an ... are compared to distinguish between individual voices. Voice ... PCs already have a microphone and can authenticate ... are most likely to be deployed in telephone-based ...
(Date:2/7/2017)... Feb. 7, 2017   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... its innovative, highly flexible and award winning eClinical solution, ... iMedNet is a proven Software-as-a-Service (SaaS) clinical ... Capture (EDC), but also delivers an entire suite of ...
Breaking Biology News(10 mins):